AMPH

$28.02+3.32%visit website

Amphastar Pharmaceuticals, Inc.

Market Cap

$1.2B

Live price × SEC shares (Jul 31, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

0.92

60mo monthly vs SPY

P/E (TTM)

16.6

TTM to Jun 2026 · diluted EPS

P/S (TTM)

1.6

TTM to Jun 2026 · revenue

P/B

1.6

Mkt cap / shareholders' equity

Flagged input, hover for details

EV/EBITDA (TTM)

10.3

TTM to Jun 2026 · EV incl. net debt

Flagged input, hover for details

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	191,840	183,105	171,171	183,903	730,019
Cost of revenue	93,194	97,435	100,849	90,433	381,911
Gross profit	98,646	85,670	70,322	93,470	348,108
Research & development	22,354	23,314	26,737	22,164	94,569
Total operating expenses	73,326	50,064	56,692	53,741	233,823
Operating income	25,320	35,606	13,630	39,729	114,285
Interest expense	6,284	6,630	6,553	6,659	26,126
Pretax income	21,513	31,914	10,052	38,544	102,023
Income tax	4,163	7,485	3,632	8,196	23,476
Net income	17,350	24,429	6,420	30,348	78,547
EPS (basic) ($)	0.38		0.14	0.69	1.74
EPS (diluted) ($)	0.37		0.14	0.67	1.69
Weighted avg. shares (basic)	46,474		45,322	43,644
Weighted avg. shares (diluted)	47,677		46,458	44,225

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 6, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 50 more quarters, back to Mar 2013, with Tormere Pro.

Corporate Events (8-K)

11 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Aug 6, 2026 accepted 4:32 PM ET	2.02Earnings release	Document SEC ↗
Jul 13, 2026 accepted 6:01 AM ET	5.02Officer / director change	Document SEC ↗
Jul 8, 2026 accepted 8:03 PM ET	8.01Other events	Document SEC ↗
Jun 3, 2026 accepted 4:15 PM ET	5.07Shareholder vote	Document SEC ↗
May 7, 2026 accepted 4:22 PM ET	2.02Earnings release	Document SEC ↗
Mar 16, 2026 accepted 6:00 AM ET	8.01Other events	Document SEC ↗
Mar 6, 2026 accepted 4:17 PM ET	5.02Officer / director change	Document SEC ↗
Mar 6, 2026 accepted 4:12 PM ET	1.01Material agreement	Document SEC ↗
Feb 26, 2026 accepted 4:24 PM ET	2.02Earnings release	Document SEC ↗
Jan 12, 2026 accepted 5:15 PM ET	1.01Material agreement7.01Reg FD disclosure	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

72%

W/W -1.5pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Velocity Score

25.65x

Avg Daily Selling (90d)

372 sh/day

Baseline Daily Selling

0.0 sh/day

Unique Sellers (90d)

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-09-21	2026-09-23	PETERS WILLIAM J	Director & CFO, EVP & TREASURER	Sale	4,139	$25.00	$103K	168.7K	View
2026-09-16	2026-09-17	Zhou Rong	SENIOR EVP, PRODUCTION CENTER	Sale	10.0K	$23.94	$239K	169.2K	View
2026-09-02	2026-09-03	Zhou Rong	SENIOR EVP, PRODUCTION CENTER	Sale	3,187	$23.63	$75K	169.2K	View
2026-08-11	2026-08-12	PRINS RICHARD K	Director	Sale	7,973	$20.30	$162K	29.6K	View
2026-08-07	2026-08-11	PETERS WILLIAM J	Director & CFO, EVP & TREASURER	Sale	8,180	$22.48	$184K	172.8K	View